Farhan Khawaja, MD
Interventional Cardiology · Orlando, FLNPI 1669489209
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Medtronic accounts for 95.0% of it on its own, with 15 other manufacturers making up the rest. 2025 is the largest year on record at $27,285, more than ten times the $565 reported in 2019. Among interventional cardiology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 256 payments — averaging $300.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$73K
- Edwards Lifesciences$2K
- Abiomed$740
- Shockwave Medical, Inc$416
- Boston Scientific$324
- Pfizer$115
- plus $477 from 10 others
Across 22 payments — averaging $25,427 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$559K
- Recor Medical Inc$500
What the payments were for
- Consulting fees$39,76952%
- Speaking & faculty fees$21,69028%
- Travel & lodging$8,25511%
- Food & beverage$7,33810%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 206 | $73,161 |
| Edwards Lifesciences | 12 | $1,820 |
| Abiomed | 10 | $740 |
| Shockwave Medical, Inc | 3 | $416 |
| Boston Scientific | 7 | $324 |
| Pfizer | 1 | $115 |
| Penumbra, Inc. | 1 | $100 |
| Cardiovascular Systems Inc. | 3 | $100 |
| Abbott | 4 | $78 |
| Bolton Medical Inc | 1 | $36 |
| E.r. Squibb & Sons, L.L.C. | 2 | $35 |
| Philips North America LLC | 1 | $33 |
| Livanova USA, Inc. | 2 | $31 |
| AstraZeneca | 1 | $28 |
| Cathworks, Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYMPLICITY G3$32,441
- COREVALVE EVOLUT R$1,829
- RESOLUTE ONYX$1,672
- SAPIEN 3 Ultra RESILIA$753
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$416
- Edwards SAPIEN 3 Transcatheter Heart Valve$381
- Impella$234
- CoreValve Evolut$165
- EVOQUE$142
- CROSSBOSS$126
- ELIQUIS$115
- GENERAL - STRUCTURAL HEART$101
- IN.PACT Admiral$100
- Indigo$100
How this compares
$77,052 in reported general payments places this provider in the 90th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 282 | $263,943 |
| EntrestoSacubitril/Valsartan | 54 | $83,629 |
| Repatha SureclickEvolocumab | 47 | $57,934 |
| BrilintaTicagrelor | 57 | $41,606 |
| JardianceEmpagliflozin | 24 | $33,741 |
| Ranolazine ErRanolazine | 38 | $4,486 |
| Ezetimibe | 147 | $4,170 |
| Metoprolol Succinate | 266 | $3,404 |
| Rosuvastatin Calcium | 282 | $3,140 |
| ClopidogrelClopidogrel Bisulfate | 293 | $3,058 |
| Atorvastatin Calcium | 258 | $2,408 |
| Losartan Potassium | 196 | $1,646 |
| Amlodipine Besylate | 195 | $1,327 |
| Carvedilol | 176 | $1,238 |
| Potassium Chloride | 42 | $909 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $115 | $263,943282 claims |
| AstraZenecaBrilinta | $28 | $41,60657 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Orlando
- Zahid AminOrlando$635K
- Bruce SteinOrlando$151K
- Aalok PatelOrlando$115K
- Vijaykumar KasiOrlando$77K
- Arthur LeeGainesville$1.8M
- Santhosh MathewsBradenton$1.4M
- Siddharth WayangankarJacksonville$1.2M
- Patrick CambierTrinity$901K
- Rohit AminPensacola$560K
- Eduardo de MarchenaMiami$498K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.